CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer

Lung Cancer

Volumn 62, Issue 1, 2008, Pages 15-22

  Liu, Zeyi ^a   Zhao, Jun ^a,c   Chen, Xiao Feng ^a,d   Li, Wenwen ^a   Liu, Rengyun ^a   Lei, Zhe ^a   Liu, Xia ^a   Peng, Xiaobei ^a   Xu, Ke ^b   Chen, Jun ^b   Liu, Hongyu ^b   Zhou, Qing Hua ^b   Zhang, Hong Tao ^a  

^a SOOCHOW UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SUZHOU UNIVERSITY   (China)

^d SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Chromosome 3p; CIMP; NSCLC; TSG

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHROMOSOME 3P; CONTROLLED STUDY; CPG ISLAND; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 3; CPG ISLANDS; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 52149091635     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.02.005     Document Type: Article

References (49)

1. Yang L., Parkin D.M., Li L.D., Chen Y.D., and Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 90 (2004) 2157-2166
2. Zhong S., Fields C.R., Su N., Pan Y.X., and Robertson K.D. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26 (2007) 2621-2634
3. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64 (2004) 3753-3756
4. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
5. Das P.M., and Singal R. DNA methylation and cancer. J Clin Oncol 22 (2004) 4632-4642
6. Zöchbauer-Müller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., and Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61 (2001) 249-255
7. Toyooka S., Toyooka K.O., Maruyama R., Virmani A.K., Girard L., Miyajima K., et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 1 (2001) 61-67
8. Toyooka S., Maruyama R., Toyooka K.O., McLerran D., Feng Z., Fukuyama Y., et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103 (2003) 153-160
9. Zöchbauer-Müller S., Minna J.D., and Gazdar A.F. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 7 (2002) 451-457
10. Gu J., Berman D., Lu C., Wistuba I.I., Roth J.A., Frazier M., et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12 (2006) 7329-7338
11. Kim D.H., Nelson H.H., Wiencke J.K., Christiani D.C., Wain J.C., Mark E.J., et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20 (2001) 1765-1770
12. Minna J.D., Fong K., Zöchbauer-Müller S., and Gazdar A.F. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 8 (2002) S41-S46
13. Kim D.H., Kim J.S., Ji Y.I., Shim Y.M., Kim H., Han J., et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 63 (2003) 3743-3746
14. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4 (2004) 707-717
15. Wang J., Lee J.J., Wang L., Liu D.D., Lu C., Fan Y.H., et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10 (2004) 6119-6125
16. Toyooka S., Suzuki M., Maruyama R., Toyooka K.O., Tsukuda K., Fukuyama Y., et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91 (2004) 771-774
17. Kim Y.T., Park S.J., Lee S.H., Kang H.J., Hahn S., Kang C.H., et al. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 130 (2005) 1378
18. Belinsky S.A., Grimes M.J., Casas E., Stidley C.A., Franklin W.A., Bocklage T.J., et al. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 96 (2007) 1278-1283
19. Katayama H., Hiraki A., Aoe K., Fujiwara K., Matsuo K., Maeda T., et al. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer 120 (2007) 2191-2195
20. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96 (1999) 8681-8686
21. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59 (1999) 5438-5442
22. Ueki T., Toyota M., Sohn T., Yeo C.J., Issa J.P., Hruban R.H., et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60 (2000) 1835-1839
23. Shen L., Ahuja N., Shen Y., Habib N.A., Toyota M., Rashid A., et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 94 (2002) 755-761
24. Marsit C.J., Houseman E.A., Christensen B.C., Eddy K., Bueno R., Sugarbaker D.J., et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 66 (2006) 10621-10629
25. Suzuki M., Shigematsu H., Iizasa T., Hiroshima K., Nakatani Y., Minna J.D., et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 106 (2006) 2200-2207
26. Zhang C., Li Z., Cheng Y., Jia F., Li R., Wu M., et al. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res 13 (2007) 944-952
27. Kuroki T., Trapasso F., Yendamuri S., Matsuyama A., Alder H., Mori M., et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63 (2003) 3724-3728
28. Riquelme E., Tang M., Baez S., Diaz A., Pruyas M., Wistuba I.I., et al. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 250 (2007) 100-106
29. Choi C.H., Lee K.M., Choi J.J., Kim T.J., Kim W.Y., Lee J.W., et al. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett 255 (2007) 26-33
30. Mountain C.F. Revisions in the International System for staging lung cancer. Chest 111 (1997) 1710-1717
31. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
32. Youssef E.M., Lotan D., Issa J.P., Wakasa K., Fan Y.H., Mao L., et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10 (2004) 1733-1742
33. Fleisher A.S., Esteller M., Wang S., Tamura G., Suzuki H., Yin J., et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59 (1999) 1090-1095
34. Kuroki T., Trapasso F., Yendamuri S., Matsuyama A., Alder H., Williams N.N., et al. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res 63 (2003) 3352-3355
35. Lo K.W., Kwong J., Hui A.B., Chan S.Y., To K.F., Chan A.S., et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61 (2001) 3877-3881
36. Liu X.Q., Chen H.K., Zhang X.S., Pan Z.G., Li A., Feng Q.S., et al. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer 106 (2003) 60-65
37. Zöchbauer-Müller S., Fong K.M., Maitra A., Lam S., Geradts J., Ashfaq R., et al. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61 (2001) 3581-3585
38. Zhang H.T., Chen X.F., Wang M.H., Wang J.C., Qi Q.Y., Zhang R.M., et al. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 10 (2004) 2359-2367
39. Oue N., Mitani Y., Motoshita J., Matsumura S., Yoshida K., Kuniyasu H., et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 106 (2006) 1250-1259
40. Ottini L., Falchetti M., Lupi R., Rizzolo P., Agnese V., Colucci G., et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 17 (2006) vii97-vii102
41. An Q., Liu Y., Gao Y., Huang J., Fong X., Li L., et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett 188 (2002) 109-114
42. Chan E.C., Lam S.Y., Tsang K.W., Lam B., Ho J.C., Fu K.H., et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 8 (2002) 3741-3746
43. Ng C.S., Zhang J., Wan S., Lee T.W., Arifi A.A., Mok T., et al. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol 79 (2002) 101-106
44. Liu Y., An Q., Li L., Zhang D., Huang J., Feng X., et al. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24 (2003) 1897-1901
45. Zhou X.M., Shao S.J., Xu G.D., Zhong R.T., Liu D.Y., Tang J.W., et al. Highly sensitive determination of the methylated p16 gene in cancer patients by microchip electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 816 (2005) 145-151
46. Xie G.S., Hou A.R., Li L.Y., Gao Y.N., and Cheng S.J. Aberrant p16 promoter hypermethylation in bronchial mucosae as a biomarker for the early detection of lung cancer. Chin Med J (Engl) 119 (2006) 1469-1472
47. Kim D.S., Cha S.I., Lee J.H., Lee Y.M., Choi J.E., Kim M.J., et al. Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer 58 (2007) 1-6
48. Brock M.V., Gou M., Akiyama Y., Muller A., Wu T.T., Montgomery E., et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9 (2003) 2912-2919
49. Suzuki M., Sunaga N., Shames D.S., Toyooka S., Gazdar A.F., and Minna J.D. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 64 (2004) 3137-3143